WCLC 2025 - Posters & ePosters-EP.12.03 Study on the Effects of Anlotinib Combined with PD-1 Antibody in Lung Cancer Rats and Its Impact on the PLGF/Flt-1 and TGF-ß1 Pathways

EP.12.03 Study on the Effects of Anlotinib Combined with PD-1 Antibody in Lung Cancer Rats and Its Impact on the PLGF/Flt-1 and TGF-ß1 Pathways

Back to course

Pdf Summary

This study investigated the effects of combined anlotinib and PD-1 monoclonal antibody treatment on lung cancer in rats, focusing on immune responses and the PLGF/Flt-1 and TGF-β1 signaling pathways. Fifty Sprague-Dawley rats were used: 10 as blank controls, and 40 randomized into four groups—model control, anlotinib alone, PD-1 antibody alone, and combination therapy. Treatments included intraperitoneal injections or gavage as appropriate. After two weeks, key immune cells—CD4+ T cells, CD8+ cells, and CD68+ macrophages—were significantly elevated in the combination group compared to the other groups, while CD206+ macrophages, often associated with tumor-promoting inflammation, were reduced. Immunohistochemistry revealed that angiogenesis was notably inhibited in the combination group, showing fewer signs of new blood vessel formation than single-agent or control groups. Molecular analyses via qPCR and Western blot demonstrated that mRNA and protein levels of placental growth factor (PLGF), its receptor Flt-1, and transforming growth factor-β1 (TGF-β1) were significantly decreased in the combination group relative to other groups. These findings suggest that combining anlotinib, a multi-target tyrosine kinase inhibitor, with PD-1 antibody enhances anti-tumor immunity, decreases tumor-associated macrophage infiltration, inhibits angiogenesis, and downregulates tumor-promoting PLGF/Flt-1 and TGF-β1 pathways in lung cancer rat models. The study concludes that this combination therapy may offer a promising approach for lung cancer treatment via immune modulation and suppression of pro-angiogenic and fibrotic signaling pathways.

Asset Subtitle

Shugeng Tang

Meta Tag

Speaker Shugeng Tang

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

anlotinib

PD-1 monoclonal antibody

lung cancer

immune response

PLGF/Flt-1 signaling pathway

TGF-β1 signaling pathway

tumor-associated macrophages

angiogenesis inhibition

combination therapy

rat model